Cargando…

PD-L1 expression in human cancers and its association with clinical outcomes

PD-L1 is an immunoinhibitory molecule that suppresses the activation of T cells, leading to the progression of tumors. Overexpression of PD-L1 in cancers such as gastric cancer, hepatocellular carcinoma, renal cell carcinoma, esophageal cancer, pancreatic cancer, ovarian cancer, and bladder cancer i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xin, Teng, Feifei, Kong, Li, Yu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990391/ https://www.ncbi.nlm.nih.gov/pubmed/27574444 http://dx.doi.org/10.2147/OTT.S105862

Ejemplares similares

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
por: Teng, Feifei, et al.
Publicado: (2020)

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
por: Teng, Feifei, et al.
Publicado: (2016)

Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
por: Xue, Song, et al.
Publicado: (2017)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
por: Lassalle, Sandra, et al.
Publicado: (2020)

Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters
por: Yuan, Chenxi, et al.
Publicado: (2019)

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer
por: Jiang, Cui, et al.
Publicado: (2019)

Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer
por: Wang, Xin, et al.
Publicado: (2016)

Optimum fractionation of radiation to combine PD‐1 blockade
por: Teng, Feifei, et al.
Publicado: (2023)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
por: Bekos, Christine, et al.
Publicado: (2021)

BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes
por: Li, Xiangmin, et al.
Publicado: (2020)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection
por: Lyu, Xintong, et al.
Publicado: (2019)

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
por: Chen, Yu, et al.
Publicado: (2020)

The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis
por: Xue, Song, et al.
Publicado: (2017)

Genetic Variation of PD-L1 Gene Affects its Expression and Is Related to Clinical Outcome in Epithelial Ovarian Cancer
por: Sun, Haiyan, et al.
Publicado: (2022)

PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
por: Mucileanu, Adrian, et al.
Publicado: (2021)

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
por: Wang, Peiliang, et al.
Publicado: (2021)

Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients
por: Wang, Weili, et al.
Publicado: (2018)

Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer
por: Wang, Xin, et al.
Publicado: (2019)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy
por: Pichler, Renate, et al.
Publicado: (2017)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters
por: Mehan, Anoushika, et al.
Publicado: (2021)

PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
por: Hong, Angela M, et al.
Publicado: (2016)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
por: Xue, Song, et al.
Publicado: (2017)

CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer
por: Zhu, Yingming, et al.
Publicado: (2016)

PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer
por: Kawasaki, Kento, et al.
Publicado: (2023)

PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer
por: Russo, Giorgio Ivan, et al.
Publicado: (2022)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
por: Wu, Chun-Te, et al.
Publicado: (2016)

Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
por: Okadome, Kazuo, et al.
Publicado: (2020)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018)

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I
por: Kong, Xiangyi, et al.
Publicado: (2022)

Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance
por: Jayaraj, Perumal, et al.
Publicado: (2019)

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
por: Xue, Chunyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nf27v7k4kebgf76nvknfdmlqtb